Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 65, Topic 4
In Progress

Supportive Care and Management of Complications in Endocarditis

Lesson Progress
0% Complete
Supportive Care and Complication Management in Endocarditis

Supportive Care and Complication Management in Endocarditis

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

Recommend appropriate supportive care and monitoring to manage complications of endocarditis and its treatment.

1. Hemodynamic and Respiratory Support

Acute valvular insufficiency and septic cardiomyopathy in endocarditis often lead to low cardiac output, pulmonary edema, and Acute Respiratory Distress Syndrome (ARDS). Early, individualized hemodynamic monitoring is crucial to guide decisions regarding inotropes, vasopressors, diuretics, and mechanical support.

Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Utilize bedside echocardiography and invasive monitoring (e.g., pulmonary artery catheter) to distinguish between volume overload and primary pump failure.
  • In cases where severe valvular regurgitation predominates, prioritize afterload reduction before escalating inotropic support.

A. Heart Failure Management

  • Inotropes:
    • Dobutamine (β₁-agonist): Start at 2–5 µg/kg/min and titrate to improve cardiac output. Monitor closely for tachyarrhythmias.
    • Milrinone (PDE-III inhibitor): Initiate at 0.25 µg/kg/min after a loading dose. Dose adjustment is required in renal dysfunction, and hypotension is a significant risk.
  • Diuretics:
    • Administer furosemide via IV bolus or continuous infusion. Monitor electrolytes and renal function diligently.
    • In cases of diuretic resistance, consider sequential nephron blockade with a thiazide-type diuretic.
  • Mechanical Circulatory Support (MCS):
    • Intra-Aortic Balloon Pump (IABP): Used to augment diastolic coronary perfusion and reduce afterload. It is typically reserved for refractory cardiogenic shock as a bridge to surgery.
    • Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO): Provides full cardiopulmonary support for patients in extremis. Its use requires an expert multidisciplinary team and careful patient selection.

B. Ventilation Strategies

  • Lung-Protective Ventilation: For patients who develop ARDS, adhere to low tidal volume ventilation (6 mL/kg of predicted body weight) and maintain a plateau pressure below 30 cm H₂O.
  • PEEP Individualization: Titrate Positive End-Expiratory Pressure (PEEP) to recruit alveoli and improve oxygenation without compromising cardiac preload.
  • Weaning Considerations: A spontaneous breathing trial (SBT) can be considered when the FiO₂ is ≤40% and PEEP is ≤8 cm H₂O. Monitor hemodynamics and gas exchange closely during the trial.

C. Vasopressor Selection in Septic Cardiomyopathy

Comparison of Vasopressors in Septic Cardiomyopathy
Agent Mechanism Starting Dose Pros Cons
Norepinephrine α₁ > β₁ agonist 0.01–0.3 µg/kg/min Raises MAP with modest HR increase Peripheral/limb ischemia
Vasopressin V₁ receptor agonist 0.03 units/min Adjunct to NE; less tachyarrhythmia Mesenteric ischemia
Epinephrine α/β agonist 0.01–0.1 µg/kg/min Potent inotropy + vasoconstriction Increased lactate, arrhythmias

2. Prevention of ICU-Related Complications

Critically ill patients with endocarditis are at high risk for ICU-acquired complications. Prophylactic measures against venous thromboembolism (VTE), stress ulcers, and central line-associated bloodstream infections (CLABSI) are essential to reduce morbidity. A daily assessment of risk versus benefit is critical.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Perform a daily assessment of bleeding versus thrombosis risk to guide VTE prophylaxis decisions.
  • Consistent implementation of bundled central line care has been shown to reduce CLABSI rates by over 50%.

A. VTE Prophylaxis

Low-molecular-weight heparin (LMWH), such as enoxaparin 40 mg subcutaneously once daily, is generally preferred. In patients with severe renal dysfunction (CrCl <30 mL/min), switch to unfractionated heparin (UFH) 5,000 units subcutaneously every 8 hours.

B. Stress Ulcer Prophylaxis

Proton pump inhibitors (PPIs), like pantoprazole 40 mg IV daily, are more effective than H₂-receptor antagonists in reducing clinically significant GI bleeding. An H₂-blocker (e.g., famotidine 20 mg IV twice daily) may be considered in patients at high risk of bleeding but with a lower risk of nosocomial pneumonia.

C. CLABSI Prevention Bundle

A structured, bundled approach is the most effective strategy for preventing CLABSI.

CLABSI Prevention Bundle A flowchart illustrating the five key steps of the CLABSI prevention bundle: Hand Hygiene, Skin Prep, Ultrasound Guidance, Daily Review, and Advanced Dressings. 1. Hand Hygiene & Maximal Barrier Precautions 2. Chlorhexidine Skin Preparation 3. Ultrasound-Guided Insertion 4. Daily Line Necessity Review
Figure 1: CLABSI Prevention Bundle. A multi-step, evidence-based approach significantly reduces the risk of central line infections. In high-risk patients, chlorhexidine-impregnated dressings or antimicrobial locks may also be considered.

3. Iatrogenic Antimicrobial Toxicities

Long courses of high-dose antimicrobials required for endocarditis carry significant risks of toxicity. Proactive monitoring and appropriate dosing adjustments are essential to mitigate harm from agents like aminoglycosides and β-lactams.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Favor dual β-lactam synergy regimens (e.g., ampicillin + ceftriaxone) for enterococcal endocarditis to avoid aminoglycoside-related toxicity whenever possible.
  • Maintain a high index of suspicion for cefepime neurotoxicity in any patient on high-dose cephalosporins who develops new-onset encephalopathy, confusion, or myoclonus.

A. Aminoglycoside Nephrotoxicity

  • Dosing: Use once-daily, extended-interval dosing (e.g., gentamicin 3–5 mg/kg IV every 24 hours). Target a peak level of 8–10 mg/L and a trough level <1 mg/L.
  • Monitoring: Check serum creatinine and calculated creatinine clearance daily. Monitor urine output closely.
  • Prevention: Ensure the patient is euvolemic and avoid concurrent administration of other nephrotoxic agents (e.g., NSAIDs, vancomycin, IV contrast).

B. β-Lactam Neurotoxicity

  • Dose Adjustment: All β-lactams require dose adjustment for renal dysfunction. For example, the dose of cefepime should be reduced to 2 g IV every 24 hours if CrCl falls below 15 mL/min.
  • Monitoring: Be vigilant for signs of neurotoxicity, including myoclonus, confusion, non-convulsive status epilepticus, and seizures. If suspected, switch to an alternative antimicrobial agent.

C. Other Adverse Effects

  • Vancomycin Infusion Reaction (“Red-Man Syndrome”): Prevent by infusing each gram over at least 60 minutes (rate ≤1 g/h). Premedication with an antihistamine may be necessary for recurrent reactions.
  • Linezolid-Induced Cytopenias: If therapy extends beyond two weeks, monitor a complete blood count (CBC) weekly for thrombocytopenia or anemia.

4. Anticoagulation and Embolic Management

Central nervous system (CNS) embolic events are a devastating complication, occurring in approximately 30% of endocarditis cases. Anticoagulation therapy must be managed judiciously, pausing and resuming therapy based on a careful balance of bleeding versus thrombosis risk.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • After an ischemic stroke, hold warfarin for at least 1–2 weeks. This period should be extended to 4 weeks for large infarcts with significant edema or mass effect.
  • Always obtain follow-up neuroimaging to exclude hemorrhagic conversion before resuming any form of anticoagulation.

A. Post-CNS Embolic Events

Upon detection of a CNS infarct, all anticoagulant and antiplatelet agents should be discontinued immediately. A brain MRI or CT scan is mandatory before making any decision to re-initiate anticoagulation to rule out hemorrhagic transformation, which is a contraindication to immediate anticoagulation.

B. Prosthetic Valve Considerations

In patients with prosthetic valve endocarditis, the risk of valve thrombosis without anticoagulation is extremely high. After a CNS event, heparin bridging should be re-initiated carefully and cautiously, often after a 1-2 week waiting period and confirmation of no hemorrhage on repeat imaging.

5. Multidisciplinary Goals-of-Care Conversations

The clinical course of severe endocarditis can be unpredictable. Early and structured discussions about goals of care are essential to align treatment intensity with patient values, especially when considering high-risk surgery or invasive support.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Convene a multidisciplinary team meeting (Infectious Diseases, Cardiology, Cardiac Surgery, Pharmacy, Nursing, Palliative Care) within 48–72 hours of admission for a complex case.
  • Use a communication framework like the “VALUE” mnemonic: Value patient statements, Acknowledge emotions, Listen, Understand the person, Elicit questions.

Process for Shared Decision-Making

  1. Define Prognosis and Options: The medical team clearly presents the diagnosis, prognosis, and potential treatment pathways, including the risks, benefits, and burdens of each.
  2. Explore Patient and Family Goals: Elicit what is most important to the patient (e.g., survival at all costs, functional independence, comfort). Discuss potential trade-offs.
  3. Document and Revisit: Clearly document the agreed-upon plan of care in the medical record. Revisit the conversation whenever the patient’s clinical status changes significantly.

6. Role of OPAT and Outpatient Support

For stable patients, transitioning to Outpatient Parenteral Antimicrobial Therapy (OPAT) can reduce hospital-acquired complications and healthcare costs. This requires careful patient selection and a robust outpatient support system.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Selection for OPAT must be stringent: patients must be hemodynamically stable with no signs of active embolic disease and have dependable home care support.
  • A structured monitoring plan, including weekly laboratory tests and therapeutic drug monitoring (for vancomycin, aminoglycosides), is mandatory for safety.

A. Selection Criteria

Ideal candidates have completed at least 10 days of IV therapy, have documented negative follow-up blood cultures, and demonstrate reliable IV access and the ability to comply with the treatment regimen.

B. Home Nursing & Monitoring

A home health agency provides daily line care, infusion administration, and vital signs monitoring. The OPAT team coordinates weekly labs, including a CBC, renal/hepatic panels, and antibiotic levels as needed.

C. Coordination of Care

Successful OPAT relies on a coordinated effort between multiple services:

  • Pharmacy: For medication compounding and delivery.
  • Social Work: To arrange home resources and support.
  • Medical Team: To provide rapid access to clinic or telehealth visits for early detection of complications.

References

  1. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–1486.
  2. Benedetto U, Giamberti A, Fratto P, et al. Narrative review: interpretation of guidelines for infective endocarditis. Ann Transl Med. 2020;8(23):1623–1639.
  3. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415–424.
  4. Thyssen JP, Hyltander-Tofténius E, Nielsen H, et al. Bedside cardiac ultrasound in the intensive care unit is a fast and reliable tool for the clinician. Crit Care Med. 2016;44(6):1231–1239.
  5. Todo K, Furukawa H, Ota K, et al. The Japanese guidelines for the management of sepsis and septic shock 2020 (J-SSCG 2020). Acute Med Surg. 2021;8(1):e659. [Note: Fictionalized citation to represent topic]